News » Archives » June 2012

$5 million gift establishes Gallagher family professorships in adult stem cell research

Author: Marissa Gebhard

Stem cell research

Alumnus Michael Gallagher and his wife, Elizabeth, have made a $5 million gift to establish the Elizabeth and Michael Gallagher Family Professorships in Adult Stem Cell Research at the University of Notre Dame.

Their gift, which will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, will strengthen Notre Dame's leadership in the field of stem cell research and enhance the University's effective dialogue between the biomedical research community and the Catholic Church on matters related to the use and application of stem cells and regenerative medicine.

Read More

Notre Dame researcher’s paper examines the biology and clinical application of tumor-derived microvesicles

Author: William G. Gilroy

Crislyn D’Souza-Schorey

A new paper by Crislyn D’Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers.

Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients. The new paper discusses the potential of microvesicles to present a combination of disease- and tissue-specific markers that would constitute a unique and identifiable biosignature for individual cancers.

Read More

Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment

Author: Arnie Phifer

A time-lapse image showing multiple myeloma cells internalizing the engineered nanoparticles

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

One of the difficulties doctors face in treating MM comes from the fact that cancer cells of this type start to develop resistance to the leading chemotherapeutic treatment, doxorubicin, when they adhere to tissue in bone marrow. "The nanoparticles we have designed accomplish many things at once,” says Başar Bilgiçer, assistant professor of chemical and biomolecular engineering and chemistry and biochemistry, and an investigator in Notre Dame’s Advanced Diagnostics and Therapeutics (AD&T) initiative.

Read More

Researchers share discoveries and progress at Parseghian scientific conference

Author: Marissa Gebhard

Marc Patterson

The second annual Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research brought together more than 100 researchers, supporters, families and children with NPC from around the world June 7-9 at the Jordan Hall of Science. Participants, representing 31 institutions and five foundations, included people from the United States, Canada, Brazil, Germany, the Netherlands, Australia and France. Scientific presentations included work in molecular and cell biology, developing diagnostics, approaching new treatments in patients, drug development, special attention to the promising treatments with Cyclodextrin, and pathological models of NPC.

Read More

International researchers collaborate at Parseghian scientific conference

Author: Marissa Gebhard

Undergraduate Sue Yi at work on NPC in a laboratory

Thirty researchers from universities and institutions around the world are presenting at the 2012 Michael, Marcia and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research June 7 to 9 (Thursday to Saturday) in the Jordan Hall of Science at the University of Notre Dame.

Niemann-Pick Type C (NPC) disease is a rare, fatal neurodegenerative disease for which there is no cure. The disease is an inherited cholesterol metabolism disorder that strikes primarily children before or during adolescence. One in every 150,000 children is affected by the disease with symptoms that include deterioration of memory and balance, lung and liver failure, delayed motor development and seizures. Through research collaboration, progress is being made on treatments for the disease.

Read More